The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRAS&lt;sup&gt;G12C&lt;/sup&gt; mutation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.